<DOC>
	<DOCNO>NCT00003943</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient metastatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Metastatic Cancer .</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate one year progression free survival , complete response rate , overall survival patient metastatic small cell cancer treat high dose paclitaxel , carboplatin , topotecan peripheral blood stem cell support . II . Assess safety treatment regimen patient population . OUTLINE : Patients receive cyclophosphamide IV 1 hour , follow paclitaxel IV 24 hour day 1 filgrastim ( G-CSF ) subcutaneously begin day 3 continue day prior last collection day . Peripheral blood stem cell ( PBSC ) collect 3-5 day . Beginning approximately 21 day follow mobilization , patient receive paclitaxel IV 24 hour day 1 , immediately follow carboplatin IV 2 hour topotecan IV 24 hour day 2 , G-CSF subcutaneously begin day 4 continue blood count recover . PBSC reinfused day 5 . Patients receive 1/3 PBSC course . Treatment repeat every 4 week 3 course absence unacceptable toxicity . Patients follow week 8 treatment , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm small cell carcinoma Any primary site unknown primary site Extensive metastatic disease Lung primaries must least one follow : Contralateral hilar adenopathy Contralateral supraclavicular adenopathy Malignant pleural effusion Distant metastases No brain metastases CNS involvement Stable respond disease prior standard therapy allow Measurable evaluable disease prior standard therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Transaminases great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min No overt renal failure Cardiovascular : Ejection fraction least 45 % No myocardial infarction within past 6 month No congestive heart failure No significant cardiac arrhythmia No poorly control hypertension Pulmonary : FEV1 DLCO least 45 % predict No severe pulmonary disease Other : HIV negative No AIDS No prior concurrent malignancy within past 5 year except basal squamous cell skin cancer No severe medical illness ( e.g. , active peptic ulcer disease brittle uncontrolled insulin dependent diabetes ) No severe uncontrolled psychiatric illness ( e.g. , severe depression ) No history drug abuse Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month prior , 3 month study No hypersensitivity E. coli derivative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : 2 prior course standard therapy etoposide platinum analog require No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
</DOC>